Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
MOTHERS~Inclusion Criteria~* HBsAg+ mothers and HBsAg- mothers will be recruited from the cohort screened during the AVERT study at 2 maternity centers (Binza and Kingasani) in Kinshasa.~Exclusion Criteria~* Any women who do not intend to stay in Kinshasa for prenatal care through delivery or who deliver at a facility other than Binza or Kingasani~* Women \<18 years of age~INFANTS~Inclusion Criteria~* Infants born to HBsAg-positive and HBsAg-negative women who receive care at Binza and Kingasani maternity centers will be recruited for participation in this study.~Exclusion Criteria~* HIV-exposed infants (those born to HIV-positive mothers) will be excluded given an expected difference in immune response in these infants and inability to recruit enough HIV-exposed infants to be able to detect these differences in immune response~* HBV-unexposed infants weighing \<2,000 grams at birth will not be eligible to receive the birth HBV vaccine. (HBV-exposed infants receive the birth dose vaccine regardless of birth weight because the potential benefit of preventing mother-to-child transmission outweighs the potential risk of vaccination in a low birthweight infant. The research team recognizes that Group B may include a disproportionate number of low birthweight infants compared to Group C, but will account for this in post-hoc analyses and if need be, will exclude low birthweight infants from the analysis to account for potential bias).~* Infants born at a facility other than one of the two maternity centers

- Gender: ALL
- Minimum Age: None
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group A: Hepatitis B exposed, with birth dose (Type: EXPERIMENTAL): The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study.
- Group B: Hepatitis B unexposed, no birth dose (Type: NO_INTERVENTION): For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B).
- Group C: Hepatitis B unexposed, with birth dose (Type: EXPERIMENTAL): Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).